Overactive Bladder

Treatments covered
Types: Patient education | Behavioral modication | Pharmacological management | Intradetrusor Botox, PTNS, SNS | Ligament surgery
Stages: Early | Middle | Late

Details
1. Tracked via the ICIQ-OAB module
2. Tracked via the OAB-q SF
3. Tracked via the ICIQ-MLUTSsex or the ICIQ-FLUTSsex
4. Tracked via the Treatment Benefit Scale

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit http://www.ichom.org/medical-conditions/overactive-bladder/

© 2023 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more Sets of Patient-Centered Outcome Measures. Version 4.0.0 Revised: January 2022
Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsors

The Working Group

Australia
George Szonyi | Sydney Local Health District
Kate Moore | St George Hospital, University of NSW

Canada
Adrian Wagg | University of Alberta

Netherlands
John Heesakkers | UMC St Radboud

New Zealand
Peter Herbison | Dunedin School of Medicine

Sweden
Ian Milsom | Sahlgrenska University Hospital

United Kingdom
Linda Cardozo | King's College Hospital NHS

United States
Anita Anderson* | Cedars-Sinai Medical Center
Jennifer Anger | Massachusetts General Hospital

*Patient representative

Ann Gormley | Hitchcock Dartmouth MC
Jessica McKinney | Marathon PT
Abraham Morse | Boston Urogyn
Samantha Pulliam | Massachusetts General Hospital

Nikki Cotterill | Bristol Urological Institute
Phil Toozs-Hobson | Birmingham Women's NHS Foundation Trust

*Patient representative